Literature DB >> 8657124

Two chimeric receptors of epidermal growth factor receptor and c-Ros that differ in their transmembrane domains have opposite effects on cell growth.

Q Xiong1, J L Chan, C S Zong, L H Wang.   

Abstract

Two chimeric receptors, ER1 and ER2, were constructed. ER1 contains the extracellular and transmembrane (TM) domains derived from epidermal growth factor receptor and the cytoplasmic domain from c-Ros; ER2 is identical to ER1 except that its TM domain is derived from c-Ros. Both chimeras can be activated by epidermal growth factor and are capable of activating or phosphorylating an array of cellular signaling proteins. Both chimeras promote colony formation in soft agar with about equal efficiency. Surprisingly, ER1 inhibits while ER2 stimulates cell growth on monolayer culture. Cell cycle analysis revealed that all phases, in particular the S and G2/M phases, of the cell cycle in ER1 cells were elongated whereas G1 phase of ER2 cells was shortened threefold. Comparison of signaling pathways mediated by the two chimeras revealed several differences. Several early signaling proteins are activated or phosphorylated to a higher extent in ER1 than in ER2 cells in response to epidermal growth factor. ER1 is less efficiently internalized and remains tyrosine phosphorylated for a longer time than ER2. However, phosphorylation of the 66-kDa She protein, activation of mitogen activated protein kinase, and induction of c-fos and c-jun occur either to a lesser extent or for a shorter time in ER1 cells. Cellular protein phosphorylation patterns are also different in ER1 and ER2 cells. In particular, a 190-kDa Shc-associated protein is tyrosine phosphorylated in ER2 but not in ER1 cells. Our results indicate that the TM domains have a profound effect on the signal transduction and biological activity of those chimeric receptors. The results also imply that sustained stimulation of ER1 due to its retarded internalization apparently triggers an inhibitory response that dominantly counteracts the receptor-mediated mitogenic signals. These two chimeras, expressed at similar levels in the same cell type but having opposite effects on cell growth, provide an ideal system to study the mechanism by which a protein tyrosine kinase inhibits cell growth.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8657124      PMCID: PMC231135          DOI: 10.1128/MCB.16.4.1509

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  53 in total

1.  Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein.

Authors:  X J Sun; P Rothenberg; C R Kahn; J M Backer; E Araki; P A Wilden; D A Cahill; B J Goldstein; M F White
Journal:  Nature       Date:  1991-07-04       Impact factor: 49.962

2.  Modulatory effect of the transmembrane domain of the protein-tyrosine kinase encoded by oncogene ros: biological function and substrate interaction.

Authors:  C S Zong; L H Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

Review 3.  Factors involved in the modulation of cell proliferation in vivo and in vitro: the role of fibroblast and epidermal growth factors in the proliferative response of mammalian cells.

Authors:  D Gospodarowicz; G Greenburg; H Bialecki; B R Zetter
Journal:  In Vitro       Date:  1978-01

4.  Rapid transformation of cells by Rous sarcoma virus.

Authors:  H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1969-06       Impact factor: 11.205

5.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

Review 6.  G1 phase progression: cycling on cue.

Authors:  C J Sherr
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

Review 7.  Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.

Authors:  T Hunter; J Pines
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

8.  Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells.

Authors:  G N Gill; C S Lazar
Journal:  Nature       Date:  1981-09-24       Impact factor: 49.962

9.  Biochemical and functional characterization of the murine ros protooncogene.

Authors:  D Riethmacher; O Langholz; S Gödecke; M Sachs; C Birchmeier
Journal:  Oncogene       Date:  1994-12       Impact factor: 9.867

10.  PC12 cells overexpressing the insulin receptor undergo insulin-dependent neuronal differentiation.

Authors:  I Dikic; J Schlessinger; I Lax
Journal:  Curr Biol       Date:  1994-08-01       Impact factor: 10.834

View more
  9 in total

1.  Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Authors:  Alan Charest; Vicky Kheifets; Julie Park; Keara Lane; Kevin McMahon; Cathy L Nutt; David Housman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

2.  RACK1 recruits STAT3 specifically to insulin and insulin-like growth factor 1 receptors for activation, which is important for regulating anchorage-independent growth.

Authors:  Weizhou Zhang; Cong S Zong; Ulrich Hermanto; Pablo Lopez-Bergami; Ze'ev Ronai; Lu-Hai Wang
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

Review 3.  The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.

Authors:  Jennifer L Hsu; Mien-Chie Hung
Journal:  Cancer Metastasis Rev       Date:  2016-12       Impact factor: 9.264

Review 4.  Molecular pathways: ROS1 fusion proteins in cancer.

Authors:  Kurtis D Davies; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

5.  Domain-dependent modulation of PDGFRbeta by ganglioside GM1.

Authors:  Janet L Oblinger; Cynthia L Boardman; Allan J Yates; Richard W Burry
Journal:  J Mol Neurosci       Date:  2003-04       Impact factor: 3.444

6.  EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis.

Authors:  C-H Shih; Y-J Chang; W-C Huang; T-H Jang; H-J Kung; W-C Wang; M-H Yang; M-C Lin; S-F Huang; S-W Chou; E Chang; H Chiu; T-Y Shieh; Y-J Chen; L-H Wang; L Chen
Journal:  Oncogene       Date:  2017-07-31       Impact factor: 9.867

7.  The Impact of PTPRK and ROS1 Polymorphisms on the Preeclampsia Risk in Han Chinese Women.

Authors:  Huihui Li; Xingyu Yan; Man Yang; Mei Liu; Shan Tian; Mengru Yu; Wei-Ping Li; Cong Zhang
Journal:  Int J Hypertens       Date:  2021-10-04       Impact factor: 2.420

Review 8.  ROS1-dependent cancers - biology, diagnostics and therapeutics.

Authors:  Alexander Drilon; Chelsea Jenkins; Sudarshan Iyer; Adam Schoenfeld; Clare Keddy; Monika A Davare
Journal:  Nat Rev Clin Oncol       Date:  2020-08-05       Impact factor: 66.675

9.  The ortholog of the human proto-oncogene ROS1 is required for epithelial development in C. elegans.

Authors:  Martin R Jones; Ann M Rose; David L Baillie
Journal:  Genesis       Date:  2013-06-27       Impact factor: 2.487

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.